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Summa ry: Ncilhcr ~ingIC'<lgcnl Ihcrap~' nor any ,ombination treatment has 
been salisfac[nry enough 10 be regarded as standard in sy~temic advanced 
Ku!)Osi sarcoma . In an auempl 10 achieve high emeiley in combinalion with 
101'1 luxicity. wc uscd a nCI>! lipo~omal formulation uf dUXUfuhicin Pharmllco-
lugic d:lw had cSlabrished a long plasma half·life. an incrca~ed al;cumulalion in 
tumor tissue .• md a dccrcase in uptake by tissues such as li ller. spleen. and 
bone marrow. In a phase I/li open·label. do~c-csc<ll<lling trial 40 male AIDS 
paticnts with <1dvan~cd K<1pQsi Siln;omil werc enrolled to receive intravenous 
"ste,llth" lipo~omal doxorubicin biwcckly <11 do~cs of 10 mg/m~ In ,. 10).20 
mg/rn: In = 27). and 40 mg/rn: 111 = 3~. The mediilll CD4 count at b<1se line was 
25f.."L After sb: cycles 112 wecks). 39 palients were eV:.llu:.lble. Thrce paticnts 
17.5';1'1 showed a complete response. which was histological1y confirmcd . A 
partiill re .,pon~e WilS documentcd in 33 patients 1857. 1. Stable discasc was 
observed in three patients 17.57.). During a median treatment duration of 25 
weeks. four patients developed stomatitis {IO'iH. and four patients II ~I ex-
perienced alopecia. The most freque nt hematologic toxicity was neulropcnia. 
Grade 4 neutropcnia was seen in 42 .57. _ and grade 3 toxicity was seen in 3!Yk 
Toxicily was dose·depcnderll and more frequent in the 40 mgfm~ stratum. 
During a mediiln observation pcriod of 25 wecks. opportunist ic infections oc-
curred in 57.5'it of the fl~tient population. We conclude Ih:lI liposomal doxo-
rubicin al dose levels of 10 ilnd 20 mgfm~ is safe and eITectivc for treatment or 
adv:.lneed Kaposi sarcom:.l in AIDS. A control1cd Irial comparing liposomal 
doxorubin to conventionill combination Iherapy is underway. Key Words: 
HIV-AI DS-Kaposi ~a rcoma-Doxorubicin-Liposomes-Vi~cerill Kaposi 
sarcoma. 
Epidemie Kaposi sareoma (KS, is one of the most 
frequent opportunistie manifestations of the ae-
quired immunodeficiency sy ndrome 'AIDSI. As 
many as 187, of H1 V·infeeted homosexual men 
present with KS tl.:!1 as an index diagnosis of 
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AIDS. FOT paticnts with AIDS-KS. their clinieal 
course. complications. and surv ival depend on the 
extent of a preexisting immunodeficicney. Gastro-
inte stinal and pulmonary KS are potentially life-
threatening:. Possible eomplications are blceding. il-
eus_ and respirator~' fa il urc. Edema of the faee or 
li mbs is a eomplication of more severe categories of 
KS . At \cast cight different antitumor chemothera-
peutic agents have been used for systemic interven-
tion when chemother.tpy was indicated 13). 
Vinea alka loids_ doxorubicin . and bleom yein 
have been administered in scveral trials. either as a 
single agent or in different eombinations 13-8). ~ei-
thcr single-agc nttherapy nor any combination trcat-
ment has bce n satisfactory cnough to bc rcgarded as 
standard in systemic advanccd KS. Although com-
binations such as doxorubicin. blcomycin . and vin-
cristine lead to comparably high response rates. 
they also result in considerablc toxicity and compli-
cation rates (7). Nineteen of 31 patients developed 
oppon unistic infection fOllowing Ihis kind of ther-
apy. as reported by Gelmann et al. (9). On the other 
hand . onl y IQIif of patient s on doxorubicin mono-
therapy 115 mg/rn: weckl y) showed even a parti al 
res po nse and no co mpl c tc rcmi ssion could be 
ac hic ved wi lh this coursc (10). 
In an attempt to achieve high efficacy in combi-
nation wüh low toxicity. we used a new liposomal 
fo rmula tio n of doxorubicin in an ope n. dose-
cscalat ing tri al. Long-c irculating "stcalth" li po-
somes are composcd of hydrogcn3tcd soy phos-
ph atidylcholine/c holesle rol/po lye th ylcn-glycoll 
dis tcarol-ph osphat id yle th anola mine ( 11). O ne 
report of an animal model showed that the pro-
longed circulation timc of "slealth " liposoma l 
doxorubicin leads 10 supe rior thcmpeulic effectivc-
ness (11). Ph armacologic dala have shown a long 
plasma half-lifc. an increased accumulat ion of the 
drug in tumor tissuc . and a dccrease in uptake by 
tissues such as li ver. spleen , and hone marrow (1 1-
13). Our objcct ive was to evaluate whclher thc cf-
fi cacy and loxicit y of Ihis kind of liposomal doxo-
rubicin warra nt fUriher randomized trials compar-
ing it to the usual eombination regimcns. 
SUBJ ECTS AND METHODS 
Study Population 
AIDS patklll~ ",ilh biopSy·pro"<,n ~dvanced KS "ere dilibk 
for 11M: lrial. All palknlS were reeruiled from 11M: 00lpalicnl ehnk 
ofllM: Medizini\che Polik linik. Khmkum InnenMadt. Uni"ersilY 
of Munkh. Germany. 
The erileria for digibilil y inc!uded KS in a se"ere ~Iage pre· 
senting eil lw:r as visce ml KS o r progreni"e disscminated CUla· 
neous disea~e wi th edema or face or limbs or with or. l lesions. 
Fu"her inclusion cri tnia were alle ;11 18 years. Karnofsk~ Slatu~ 
>505f. white blood eeU count > 2.00011'-1.. hemogJobin > 10 g/dl. 
30nd pl3olel<'15 of > SOJKIOlI'-L. Onl~ paticnu " 'ill1 a posIlIve HIV 
anl ibody status (ELISA and Weslern blOl) " 'ere cligiblc. 
ElIdu~ion eril<'ria "'ere aeule oppc)l1unlnic infeel ions or non-
Hodgk i n'~ lympl1oma. systcmic chemothcrap~ or r.ldialion or 
KS within 4 " 'eeks prior to enlry into the trial. and major psy· 
e hiatrie iIIne~s. No suhj<'elS with cardiae ra llure werc permitted 
to pa" icipate. 
The pati<'nls g.ll\'e ",riUen informed consenl. The concomilant 
U!>C of nuclcosidcs witl1 anli·H IV aelivi ty " 'as not prol1ibllcd. nor 
was medica tion for prophylaJIis of I'ntum'K~'Jlij curinii pneu· 
monia and !>Ccondary proph ~'laJlis or oral eandidiasis . 
Evaluation and Classifi cation of Participants 
The b~selinc evaluation consisled of a med lcal hi story and a 
pl1ysical ~~amination. All "isiblc KS luions were eval ua tcd for 
~u rfacc arc~ in mm: antl nodularity . Adtlilional sonographie mea· 
surcmenlS of tumor volume in a \UhS<'1 of seHn pa ticnts in ll1e 
~()..mg slratum " 'ere performed aeeordins to a melhod rcponcd 
previously tl4- I6I. 
Thc follo"l nll laboralOl)' e"aluatlOnS "ere perfonned: White 
biood celJ count. including a dlfferenlial count. plateleu. hemo-
globin. ncaunlnc. blood urea nilrollcn. bili rubin . allalinc plIrn;· 
p11818se. transammascs. sodium. polassium. c~ l ci um. serum al· 
bumin and electrophorem. crythrOCYle s<,dimentalion rale. and 
immunoc~tolOIlY IT cells. B ce ll s. CD4. CD81. Ea. 11 patient had 
an dectrocardiogram 112 lead). an echocardiogram. a e hest 
rocnlgeoogram. and an abdominal sonography. In p3olient~ "ith 
~)' mptoms or signs suggesti"c or ga5lro1nlcstinal KS. addilional 
cndoscOfl~ "-"5 pcrformcd. Bronc~opie e"aluation was dOll<, 
in pal ien\< ,,-here pulmonary in"oI"emenl wn susp«ted by 
chest rocnll1enogram or pulmonary eompuled tomography. 
DurinS the course or therapy. the paticnls " 'ere evaluated 
wec l ly. Tl1c " 'eckly reevaluations cansis t<'d of a hislOry and a 
blood count and. ir clinically indicated . fu"her diagoostje proce· 
durcs ",'ere implemented . Biw.-ckly. KS was assesscd as Slated 
for t~ tValualion at bas.clinc . Palients reaching a cumulati ve 
dose of 300 mllm: of hposomal doxorubicin " 'cre rec"a.!uated by 
elcc trocardqram and cchocardiogram . 
Classifkation ur H IV discasc ",.5 canied OI.It aecotdinllO 11M: 
defini tions of ll1e Centers ror Diseasc Control. KS stages " 'erc 
diagnosed as proposed by the AIDS Clinica l Trials Group 
(ACTG) using ll1t Tumor- Immunc 5ystem-Systemk illneS5 
S~'stem (TIS) (171-
At baseli".. . five la rgel lesions lhal "'ere rcpresenlali"e in 
lerms or si~e. di~tribution. and nodularity " 'cre sclect<'d. docu· 
mented. and measured. Response Criltria ""n<' applicd as rce· 
ommcnded by the AcrG (171. A complete respons.- tCRI was 
defined as the absence of any deteelable r<'sidual diseasc. indud-
ing tumor·asso<:iated edema. In ease of r<'mainins maeula r le· 
sians. a biopsy docum<,n ting histololical absence of malignant 
cclls was rcquired. The respoons.- was only rated camplete if il 
lasled for 31 least 4 wecks. 
A panial re~pon~e IPRl was deflned as either ~~O'k dccreas.-
in tl1e sum of Ihe areas ur 811 pre,·iOl.lsly ui~ting lesions (SUrTo-
gate:targel le~ions) II~tinl for ~4 wceks or ;11 75% deerease in th<, 
nodularily of all previously ellisting lesions. Thc 1'1I1ingof PR WIS 
only permined ir 110 new slin or oral Icsions appcared and if 
KS·related edcma did not wvrs.cn. 
Stable di~case ISDj was defincd as any response nOI meeting 
the crileria ror e R. PR. or prosrcssi\'e d isease . 
Progressive disease was defi ned as any occurrcnce of ncw 
lesions. an inereasc or > 25% in tl1e si7.c of prcviously uist inl 
Ic~ions. or the incrcase or ed<'ma or effusions. 
Patients "cre considered eligible for tIM: evaluation or anlitu-
mor r.-spoonse arter at least IWO cyeln of Iherapy (cycle -
2' ''''cek period from dosing tv physical cxamination and labora-
tory re<,xamination at da~ 14 ). 
Treatment Schedule 
Liposomal eneapsul31ed dOAorubicin " 'as adminislcred bio 
"-eekly inll'11venously at doscs of 10 m&lm1ln • 10). 2{) mglml (n 
- 27). anti 40 mg/m' (n • )). In case ur sroide 3 or 4 toxicily. 
Ihcrapy was ;n terruptcd unl;l abnormal va lucs or signs rClurned 
1031 least snde 2 10"idIY. In ca5C of gradc ) or 4 nculropcnia. 
Ille administralion of G-CSF was allo"'·cd. Patienu in Ille 4().mgl 
m' str,lIum wcrc scheduled 10 rcccive lO mglm! ir a se'·cre Ireal· 
menl.rel&led toxic ity occurred. Enrol1ment began in No'·ember 
1991 . Thc cutoff date for analysis was Deccmber 31. 1992. After 
comple tion of Ihc fi rst six cycles. all pal ienlS were eligiblc to 
conlinue Ille treatment in ordcr 10 prcvenl relapse. 
Liposomal doxorubicin was supplied by Liposomc Tcchno!· 
ogy. Menl0 Park. CA. U.S .A. 
RESULTS 
Baseline Staging of HIV Infeclion and KS 
Thc patient population consisted of men with a 
mean age of 39.3 ;!: 8.7 years. Thirt y-nine patient s 
werc Caucasian: one was Hispanic. At baselinc , 23 
patients (57%) were classified CDC IV C 110 duc to 
a history of an AIDS-defining opportunislic infcc· 
lion . Ten patie nts (25%) had AIDS-relatcd comple" 
and fulfilled the criteria for classificat ion as CDC IV 
C2fD. Five patienls (12.5%) were classified as CDC 
IV A/D. and IWO patients (5%) had CDC IV D 
("only" KS). 
The classification of KS according 10 TIS stages 
(17) is shown in Table 1. Poor risk evalualion (T ,) 
was presenl in 28 paticnts (70%), and a CD4 count 
< 2001 .... L at baselinc was noted in 38 patients (95%). 
Thc median base line CD4 count was 25/J.lL. 
Oral und gast rointestinal KS was prescnt in 29 
(72.5%) and nine (22.5%) patients. respeclively. 
Four patienls had proven pulmonary KS (Table 2). 
Efficacy 
Thirty·nine patients were eligiblc for evaluation 
of Ihe efficacy of lhe treat ment . One palienl did not 
receivc more than one cycle oftherapy; he was hos· 
pitalizcd for a severe MAI infeclion that was not 
TABLE I. TlS HUfJi"fJ 0/ KS i" 40 pUli .. "IS , .. ,-.. i,·i" K 
IipoJ omu! JOXfJl"ubi .... " 
TlS ~ tag~ Number or paucnt ~ • 
T,I ,S, 
" 
62 . ~ 
Tol ,S , 
" 
JO.O 
T ,loS, , , 
T,I ,S. 2 . ~ 
To .. good risk leonfined 10 ~ kin and GI" I)·mph nodn and or 
minimaloTal KS: T , .. paar ri~k {tumor·a)soclatcd edema or 
ulcera tion: KS in olher ,· i ~cera): I" .. C04 I )"mphocyle~ ;> ~OOf 
,..1.: I , .. CD4lymphQ(ytc~ < 200,,..1.: S" .. no h'\tory oroppar· 
tuni~t;c infcelion OT l h T\l ~h. no B s)mplom): S, - histor) or 
oppar1unist ,c ,nreellon GI" thrush : Karnofsk) status <7~ . OIMr 
HIV·rclaled (IInu ~ . 
TABLE 2. p, .. st"lalio" 0/ Kaposi sonoma u/ bus~I;" .. ; 
/Ol'oli!ulio" und ,·ü,-",u/ i,,'·ol'· .. m .. '" 
NumbeT or palicnu 
" Edema 16 .. 
hcad 4 10 
lo .... ·er Ulrcmily 
" 
21.5 
scrotum l , 
pc<:lor;l.l re&ion , U 
Oral KS 19 72.5 
Gastrointestinal KS , n.s 
Pulmonary KS , 10 
apparent al baseline. In an intention-to·trea! analy· 
sis. afler six cycles (12 weeks), three patients 
(7.5%) showed a complele response that was con-
firmed histologically . A partial response was docu-
mented in 33 patients (85%). Stable di sease was ob-
served in three patients (7.5%). No palienl showed 
evidence or progressive di sease (Table 3) while on 
continuous Iherapy_ 
In a subset or 22 lesions. the tumor volume was 
determined by ultrasound before and after therapy 
(n = 7. palienls in Ihe 20-mg/m~ stnHum). The av· 
erage baseline volume or 536 mml :!:690 mm3 de-
creased by 90% 10 51 mm1 :!: 140 mml (p < 0.0 1; 
paired Studenfs I test). 
Toxicity 
Ad ve rse evenlS, tOX IClt y, and occurrence of 
AIDS-defining evenh were monilored during Ihe 
study period and follow-up to generate additional 
information about the long· term feasibilily of ther-
apy with liposomal doxorubicin . The median obser-
vation period was 25 weeks. The median cumula-
live dose was 175 mg/m~ . As expected , at this low 
dose level no clinical evidenee of cardiac toxicity 
was observed . 
TABLE l . RtJpo"u 0/ KS /" J9 1",·uluubl .. pfl/i .. "u rrl"UI .. d 
.. 'rh UpOlomu/ d(J~"'I.bk", j"lru'·tlluuJly ~, ... ,.,. 1 .. · .... Iu 











respon~ CCRI 0 , ".11 ~ 31U) 
Pa",al 
rc)pon~e tPR I 7 
" 
n .• . " 33184.61 
Slable 
disca)e IS DI , 0 ".3 . ~ 3 f7 . ~1 
Progression 0 0 n .3." 0101 
• S ot applleable. beeau~c al1 pauents on 40 m, ml had to be 
s"-ltchcd 10 ~O m, m" pnor to (,·, IU31iol\ . 
Ouring the whole treatment pcriod (i.e . . induc· 
tion (herapy and follow·up : median . 25 weeks). four 
patient s devcloped stomatitis (lifk) and 21 patient s 
(52.59/:) reported some degrec of alopeeia. Four of 
those 21 developcd completc alopeeia tTable 4) . 
The most frequent hematologie toxicity was neulro· 
pcnia . A tOlal of 17 patients (42.57f) cxpcrienccd 
grade 4 toxidty. Another 12 pat ients showed grade 
3 toxicity (Tablc 4). A concomitant use of G·C$F 
rcsulted in postponement of only 15% (55 of 368) of 
seheduled treatment eycles . 
Dose·related Toxicity and Efficacy 
In the high·dose group (40 mg/m~). severe loxicity 
was observed in three of three paticnts after 6 
weeks of treatment. One patient had complete 
alopecia: two had grade 4 neutropcnia. All patients 
in (his group had to be switched to 20 mg/m ~. which 
was beller tolerated in the subsequent course. 
Three patient s initiall y allocated to the 10 mg/m1_ 
dose group were switehed 10 20 mg/rn! because as 
early as 5 weeks after interruption of chemotherapy 
new lesions of KS appeared. In two pittienls. Iher· 
apy was interrupled due to inlercurrent infeclions. 
In the third patient. treatment was postponed be· 
cause he chose 10 stop therapy te mporaril y after an 
inilial satisfactory result . However. 6 weeks Inler. 
liposomal doxorubicin again was effectivcly admin· 
iSlered at the dose level of 20 mg/m!. 
Nausea. stomatiti s and constipalion were the 
most common adverse events: none of Ihem was 
severe enough to terminale chemotherapy in (he 10 
and 20 mglm2 groups. The mosl common loxicity 
was neutropenia. A lotal of 72% showed either 
grade 3 or 4 toxicity al some poinl during the ob· 
servation pcriod (Table 5). 
TABLE 4. Ad,·uJf' ... ·nu duri"J( bi ... ukl ... Ii/WSQmul 
duwmbir;i" 'Irerap)' Idllri"l1 mf'diun Qbs .. n·ut;v" puiod vI 
15 I<'''- /;sl 
Do<.c level 





Nausea 0 , ) 4 (10) 
Stomaüt;$ 0 , , 7 (1 1.5) 
ALopecia 
(eomp!ctc) 0 ) 4 ( 10) 
Cons!ipation 0 , , S (tU) 
Clinica l 
evidence of 
eardiOloxiei tY" 0 0 0 0 
• At mean eumulati,'c dmage of 175 mw'ml. 
AIDS·defining Evenls and Infections 
AIDS·defining events observed whi le patients 
were on therapy (induction therapy and follow·up) 
were opportunistic infeclions (n = 23) and non· 
Hodgkio's lymphoma (N HL) (0 = I). Si}!. palienl s 
developed ulce ral ing oral or genitoanal herpes. 
Four had a relapse or first episode of candida· 
esophagilis: in seve n patients. MAI infeclion was 
detecled: seven olhers dcveloped CMV manifesta· 
tions (n = 4. CMV retinil s: n = 3. olher CMV 
locali zalions). One patient developed cerebral tox· 
oplasmosis. In two pat ients. more Ihan one oft hose 
infcctions were diagnosed. 
Non-AIDS·defining evenlS induded oral Ihrush 
(nine episodes). herpes si mplex (eight episodes). 
pyomyosit is (four patients). and Olilis media (one 
patient) . Ninetccn of Ihe original 40 subjeclS died 
dudng (he (median) observation period of 25 weeks 
(n = 18) or were lost (0 fo llow up (n = I) . Causes 
of dealh induded MAI infee tion. wasling syn· 
drome. NHL. and cerebral toxoplasmosis. 
DlSCUSSION 
The resullS of ou r open. dose-escalating stud y 
dearly demonSlrale a high response rate after a sin· 
g1c·agenl course of liposomal doxorubiein. The 
overall response rate (CR + PR) was 92.5%. Com· 
plele response is a rare evenl in chemotherapy of 
advanced K$. However. afler Ihe administration of 
20 mglm2 of single·age nt li posomal doxorubicin. a 
hislologically prove n CR was achieved in three pa· 
tients (7.5%). Moreover. an exceplionally high per· 
centage of patient s had a part ial response. and in a 
substantial number of patient s. long·term Irealment 
(median duralion. 25 weeks) was feasib le. 
The results of an ACTG protocol on single·agent 
conventional doxorubicin have been reported for 26 
patients with a eomparable tumor burden and slag· 
ing of HI V disease (10). Ooxorubid n was appl icd at 
a weekly dose of 15 mg/m2. In the group ofpatie nt s 
with advaneed disease. no CR was ac hieved. There 
was also no partial response asjudged by the same 
criteria cmployed in our study . Eighteen paticnts 
(69%) showcd a "minor"" response: "minor"" was 
defined essent ially as any fl attening of the nodular 
indicator le5ions. However. eomparison of our dala 
with the result s of other trials depends on the com· 
parability of response eriteria. The dose levels es· 
tablished for the conventional therapy were higher 
than for liposomal doxorubiein therapy : A monthly 
TADLE 5. HCllwtol"lIic /oxid/y i" purien/.f ucej,'inj( biwakly Iipo . ."m<J/ dO.wruhid" Idll,in j( ",,,dill,, "hun'ali,,,, period "f 
25 ~·"ek.H 
NeUlropcnia 
grllde 4 < 5001 ... L 
grade J 500-999/I'L 
grllde 2 1.()()()... 1.499I ... L 
srade I 1.500-2.000I ... L 
Thrombocylopcnia 
grade 4 < 2~.000JI'L 
grade J 2~.()0(J....4'J.99':II ... L 
grade 2 50.000-74.99':II ... L 
grade 1 7~.()()(J....1OO.O()0II'L 
~ P.Jlic nl ~ wilh ba,..,linc counl > 2.UOOl ... L. 









dose or 40 mg/m! or liposomal doxorubicin (20 mg/ 
m~ biwee kl y) was used in our trial. This is 20 mg/m~ 
less Ihan the dose in the Irial reported by Fischi CI 
al. (10) (Lc .. 60 mglm ~ per monlh). 
The ove rall responses reported in olher single-
agent studies were as folIows: 26% wilh vinblastine 
(18).48% wit h bleomycin (5). and 48% wilh vincris-
tine (]9). Any comparison or Ihose trials 10 our re-
su lts may not bc valid because the st udy popula-
tions and response cri leria are not identica1. 
The rationale behind combi ni ng several chemo-
therapeutic agcnts 10 Ireat AIDS-KS was thaI thi s 
regimen would enhance efficacy while keeping tox -
icity at an acceptablc level. Using a combination of 
doxorubicin. blcomycin. and vinblastine . Gclmann 
el a1. reported an overall response (CR + PR) of 
84% (9) . In another study. two different dosages of 
doxorubicin. vi ncris tinc. and bleomyc in were 
te sied (20). The overall respon se rate was 79<ft . In 
yel anot her serie s. eombining bleomyein with vin-
cristi ne in patients wilh neutropenia resulted in a 
7?o/r: response rate (8). The rrequeney or opportu-
nisl ic infections that oceurred in assoc iation wilh 
these three eomb inat ion regimens ranged from 61 % 
to 89% of all treated patient s f4-8. 10.18). 
Liposomal dox.orubiein . as shown in our result s. 
ach ieved Ihe same range of efficacy as the se eom-
binalion therapies. The rate or opportuni st ie inree-
tions was 57.5%. Whether these data indieale thai 
single-agent liposomal doxorubicin at a dose level 
of 20 mglm~ is superior to combination chemot her-
apy ror AIDS-KS patients with advaneed dise ase 
has yel 10 be determined. We are now addressing 
this hypothesis in an ongoing randomized multi -
ce nter trial comparing the relative effieacy and 10X-
Dose lc~cl 
----- TOlal 
20 mglm' 40 mglm~ 
101 101 n ~t;;) 
-
---
IJ , 17 (42 .51 
9 0 12 001 




, 0 2 (5) 
I 1 4 (10) , U 3 (7.~). , c2.~)· 
icit y of liposomal dox.orubicin to the combination or 
blcomye in and vincristine . 
In a patie nt populat ion with advanced AIDS-KS 
lind severe im munodefie iency (median baseline 
CD4 count. 25/j.lL). a cert ain number or opportu-
nistie inrections is 10 be expecled. even irthere is no 
chemolherapeut ic intervention ror KS . A coneom-
itant anti ret rovira l therapy in all patients could rur-
ther reduee the number of opportunislic inrections. 
In patienls with neutropenia who take a eombina-
tion or liposomal doxorubiein and zidovudi nc. the 
use of zalcitabine and didanosi ne might contribute 
10 an improvement of immunologieal func tion and 
survival. 
Initial studies or the pharmaeokinet ics or these 
drugs indicated a high degree or d rug de livcry to KS 
tumors (12). The long eircu lat ion period or liposome 
rormulations thaI incorporate a synthetie polyethyl-
ene gl ycol-derived phospholipid has a pronouneed 
efrect on liposome li ssue distribution . A consider-
able increase in pharmacological efficac y can be ex-
pected (12) . Li posomes carry polyethylen-glycol on 
the surface : Ihe high vascularization or KS lesions 
in combi nation wit h an abnormal permeabili ty or 
capillaries result s in a higher proportion of the drug 
be ing deposited in tumor tissue rat her than other 
tissues 111.2 1). Thererore. toxieity levels would be 
lower tha n with conve nlional doxorubicin. Some 
palients experieneed adverse evenls like those seen 
wilh free doxorubiein. Nausea. stomatitis . and con-
stipation were the most eommon or these adverse 
events: none of Ihem was severe cnough to requ irc 
termi nation of e hcmot hcrap~' in the 10 and 20 mglm~ 
groups . . -\Jopecia and neulropenia . however. oe-
eurred in all three patie nts receivi ng 40 mglm~. re-
s u ltin g in dose imerru pt ion and a switch to 20 
mg/rn!. 
The most common tox icity was neutropen ia. b ut 
the concomitant use of G·CSF was not prohibited 
by t he protocol. Th us, only 15% of all sc heduled 
cyclcs had 10 bt; post poned. The availability and the 
use of G·CS F in Ihis open t ria l may Iherefore have 
indirecl ly cont r ibuted 10 the high overall response 
rate. Most e pisodes of neulropenia. o n the other 
hand, occurred late in the course of therapy or dur· 
ing the follow.up t reatment. T herefore. only ami-
nor influence on response rates would bc expected. 
In a mouse model tes t ing the myelosuppressive 
activity of doxorubicin e ncapsulated in liposomes 
of diffe re n t size and com posit ion, it was demon-
strated that deliver y of doxorubicin to the bone 
marrow depe nds o n the size o f t he liposomes (13). 
The use of a diffe rent fo r mulat ion. resu lting in 
smalle r liposomes. cou ld lead to a reduction in the 
myelosu ppressive action o f liposomal doxorubicin . 
Overa ll . li posomal doxorubici n was fai rly weil 
tolerated by our patie nts; the only dose- limiting tox-
icity was neulTopenia. We conclud e that at dose 
levels of 10 a nd 20 mg/m2, liposomal doxorubicin is 
a safe a nd effcctive d rug fo r t he Ireatment o f ad -
vanced AIDS-KS. A controlled trial comparing li-
posomal doxoru bici n 10 a conventional combination 
of b leomycin and vincristine is underway. 
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